We have previously identified the oncogene rgr (ralGDS related) in DNA derived from a rabbit squamous cell carcinoma. Here we describe the identification of the human orthologue of the rabbit rgr gene termed hrgr (human ralGDS related). Four alternatively spliced fulllength hrgr transcripts were isolated from normal human testes and liver libraries. Truncation of hrgr confers transforming ability to its cDNA. Using a RT -PCR assay we have been able to detect the expression of an abnormally truncated transcript in several human T-cell lymphoma lines, and in fresh tissue samples of patients with T-cell malignancies. In the DHL cell line, an Anaplastic Large Cell Lymphoma (ALCL) line, a DNA rearrangement was detected within the hrgr gene region. We propose that these T-cell lymphomas, at least in part, owe their malignant phenotypes to genetic alterations of the hrgr gene. These findings also raise the possibility that mutations in the hrgr gene are involved in other malignancies.
Introduction
Analysis of the molecular bases of cancer have resulted in the identification of a number of genetic alterations affecting a subset of genes involved in control of proliferation, survival and differentiation. Oncogenes are one of the most important groups of genes involved in the pathogenesis of cancer and they often exert their transforming effects by subverting the normal signal transduction pathways in the host cell.
We first identified the rgr oncogene as one of the two components present in the rsc oncogene (D'Adamo et al., 1997), which we isolated from a DMBA-induced rabbit squamous cell carcinoma using gene transfer and the nude mouse tumorigenesis assay (Leon et al., 1988) .
Rgr is highly homologous to RalGDS, with a 40% overall identity, increasing to 72% over a 100 amino acid region. RalGDS is a guanine nucleotide exchange factor (GEF) that activates its effector, the Ral GTPase, by dissociating the bound GDP and allowing the binding of GTP which results in Ral activation (Albright et al., 1993; White et al., 1996) . Like RalGDS, Rgr also dissociates GTP from Ral A (D' Adamo et al., 1997) . We have further shown that rgr induces phosphorylation of ERKs, p38, and JNK kinases, and it increases the levels of GTP bound Ral and Ras (Hernandez-Mun˜oz et al., 2000) . The importance of these activities is confirmed by experiments in which dominant negative Ras, Ral, and Rho block the transcription activation induced by rgr. However, only dominant negative Ras inhibits rgr transformation, indicating that Ras activation is crucial for the transforming activity of rgr (Hernandez-Mun˜oz et al., 2000) .
In the present study we have isolated the human orthologue of the rabbit rgr gene, hrgr. Moreover, we have also isolated mutant hrgr transcripts from lymphoid malignant cell lines and tissues. Similarly to the activated rabbit gene truncated form (rgr oncogene) the human mutant transcripts are truncated and oncogenic. The observation that the hrgr gene is present in truncated forms in T-cell lines and some types of T-cell lymphomas, strongly suggests that hrgr has a pathogenic role in lymphoid neoplasms.
Results

Identification of the human rgr orthologue
To determine if the rgr gene is involved in human cancer, we decided to identify its human orthologue (hrgr). We first utilized the GCG program BLAST and search for human sequences homologous to the rabbit rgr. We identified two sequences, one corresponding to a genomic sequence and the second corresponding to a 112 bp EST sequence, isolated from the mRNA of the Jurkat cell line.
When these two sequences were compared with the rabbit rgr cDNA, although they did not contain any significant overlapping regions with each other they were homologous to different regions of the rabbit gene. To further characterize these products, we obtained additional DNA sequences after extension using various RACE strategies. The extension by RACE of the EST sequence, performed using mRNA from Jurkat cells, allowed for the identification of a shortened cDNA when compared to the rabbit cDNA. Nevertheless, this human cDNA contained a 5' ATG starting codon with an appropriate open reading frame encoding a putative polypeptide with an approximate expected molecular weight of 22 KD. Upstream genomic sequences contained the other EST and had high homology to the 5' portion of the rabbit rgr gene. A complete sequence of the full-length cDNA for the human rgr gene is presented in Figure 1 .
Northern analysis showed that Jurkat cells expressed the hrgr gene at very high levels, but the transcript was much shorter than predicted by examining the hypothesized exons and by the size of the rabbit rgr cDNA (Figure 2a ). In addition, when an identical Northern was probed with the 5' homologous hrgr sequence, no hybridization was seen with Jurkat mRNA (Figure 2b ). These observations led us to hypothesize that the hrgr transcripts from the Jurkat cells might not contain the 5' region of the transcript.
Identification and analysis of the full-length normal hrgr sequence
Three full-length hrgr sequences were isolated from a testis library. The sequences contained all of the hypothesized exons in addition to the nucleotide sequences found in the Jurkat cDNA (Figure 1 ). The GenBank Accession number is AY101396. The map shows the intron/exon junctions and the amino acid sequence. The amino acid sequence is highly homologous to the RalGDS family of proteins. The comparison of the amino acid sequence of the hrgr with those of rabbit rgr and other RalGDS family members showed that the family member with the highest homology to hrgr was rgr, indicating that hrgr is in fact the orthologue of rabbit rgr. In addition, using the GCG program BLAST, hrgr is the human gene with the highest similarity to the rabbit rgr gene in the human database. The homology of hrgr with the RalGDS family of proteins runs through the whole coding region starting at 7440 in Figure 1 . The only region without homology to the RalGDS family is the shaded area in Figure 1 , which may be an intron since, although it was not excised in the transcripts we isolated from the cDNA libraries. The location of the hrgr gene was found to be at chromosomal position 22q11.2. This could be of significance because translocations at this location are frequently seen in human tumors.
The tumorigenicity of the Jurkat hrgr transcript
A significant difference between the transcripts from the Jurkat cell line and the normal transcript, besides the lack of the 5' end, is that Jurkat transcripts contain a 5' exonic sequence that is intronic in the normal transcripts. This additional sequence contains a start codon that maintains the same reading frame present in normal transcripts (Figures 3 and 4) and allows the truncated Jurkat transcripts to be translated. To determine if the truncated transcript present in Jurkat cells has transforming potential we made several eukaryotic expression constructs with the truncated Jurkat transcripts and the normal hrgr transcripts isolated from mRNA of human testes (Figure 3 ). NIH3T3 cells transfected with the Jurkat constructs were found to have a transformed phenotype ( Figure  5a ) and they were able to grow in the soft agar assay Figure 1 The nucleotide and amino acid sequence of the human rgr cDNA. The initiating ATG is underlined and italicized. The intron exon junctions are denoted by vertical bars. The amino acid sequence deduced from the open reading frame is written in the one letter code below the corresponding codons. The nucleotide sequence that is conserved between the Jurkat transcript and the normal tissues is underlined. The first in frame stop codon has an asterisk underneath it. A possible alternative initiating ATG is underlined at position 7440. A potential intron is highlighted, although it was not excised in any of the tissues that we tested. In some cases an additional exon is present between the exons presented in this map (see Figure 4) ( Figure 5b ). Additionally the clones expressing the truncated Jurkat hrgr transcripts could also grow in low serum (1%) (Figure 5c ). Cells transfected with the full-length hrgr cDNA acquired none of these properties.
The detection of several hrgr splicing variants
Sequencing analysis of multiple truncated and normal hrgr cDNAs showed that the 3' region of the gene could be represented by numerous splice variants in both the normal and truncated gene products ( Figures  3 and 4) . Interestingly, in almost all cases the reading frame was maintained. The exception to this was that some transcripts presented additional exonic sequences between the 12 and 13 exons. Depending on the presence or not of these additional exons different reading frames were used in exon 13 ( Figure 4) . The presence or absence of these exonic sequences provides a significant degree of diversity in amino acid sequence, translation stop codons, and therefore, protein size. Additional exonic sequences between the 8 and 9 exons were also seen only in the abnormal transcripts from tumor cells (Figures 3 and 4) . The presence of these exonic sequences allows for the addition of a start codon, which maintains the reading frame of the normal protein. Because all these abnormal transcripts have additional 5' exonic sequences not present in the full-length normal transcripts, it is possible to screen for the abnormal transcripts by looking for the presence of these new exonic sequences in transcripts from cell lines and tissues. This was done using RT -PCR with the primers shown with an asterisk in Figure  3 .
Using this approach, we screened the RNA from several human cell lines and human tissue samples from either normal individuals or patients with T-and B-cell malignancies (Table 1) . DNA sequencing of the PCR products derived from neoplastic samples confirmed the specificity of the products and documented the presence of 5' exonic sequences of the hrgr gene within these abnormal transcripts. As shown in Table 1 all normal lymphoid tissue samples were negative. While several human cell lines derived from T-cell malignancies were positive (CEM, DHL, Karpas and Jurkat), none of the B-cell lymphomas was positive. In addition, a number of fresh samples derived from T-cell malignancies scored positive (see Table 1 ). It is important to emphasize that a number of the positive samples were derived from Peripheral TCell Lymphoma (PTCL) patients. We therefore propose that the hrgr gene may be involved in the pathogenesis of some T-cell lymphomas.
To further investigate the pathogenic mechanisms leading to generation of the hrgr truncated transcripts, we performed Southern blotting analyses of Jurkat and other T-cell lines that were positive for the abnormal transcript by RT -PCR. By comparing the pattern profiles of normal genomic DNA with those of Jurkat we found that the hrgr bands from CEM and DHL appear to migrate at a slightly different mobility with two restriction enzymes, but the results were inconclusive (data not shown). As an alternative, to determine the molecular mechanism of activation of the abnormal hrgr transcripts, we used the GeneRacer technique to analyse the 5' region of the DHL cell line hrgr transcript. Using this approach we demonstrated that the PCR derived band of DHL had a different molecular weight when compared to the products of Jurkat or normal human cDNAs. We found after subcloning and DNA sequencing that the DHL GeneRacer RT -PCR product contained sequences in its 5' region, which corresponded to residues normally present within the 3' region of the hrgr gene ( Figure 6 ). The rearranged sequence does not involve coding regions (the start codon is the same for the DHL and Jurkat transcripts). Nevertheless, it indicates that the genetic event responsible for the production of the abnormal transcript in DHL cells is a genetic rearrangement that allows abnormal exonic sequences to be used, producing a truncated transcript (Figure 6 ). This could explain why in this cell line the truncated transcript is made. Further analysis should determine if this type of rearrangement is seen in other cell lines and tumor tissues that express the truncated transcript.
Discussion
Determination of the nucleotide sequence of the human rgr orthologue, hrgr
The goal of our study was to identify the human orthologue for rgr. To find the hrgr gene, we first searched the Genebank databases. We identified one EST from Jurkat cells and one genomic sequence that had high levels of similarity with the rabbit gene. When we used RACE to amplify the cDNA corresponding to the region of the genomic sequence that had been found in the database, the cDNA for this hypothesized transcript could not be found by RT -PCR or Northern analysis using Jurkat cDNA. Since we had identified the rabbit rgr oncogene in a truncated form, we hypothesized that a similar process might have occurred in the Jurkat tumor cell line. We then isolated the normal transcript from a human testis cDNA library. From this library we isolated and sequenced three slightly different cDNA transcripts. These transcripts were nearly identical to the hypothesized full-length sequence. This full-length cDNA sequence from testes varied from the truncated cDNA derived from Jurkat cells in two ways. First it contained several 5' exons that were missing from the truncated sequences. Second, it lacked exonic sequences that the truncated transcripts have at their 5' ends. These abnormal exonic sequences afford the truncated transcripts a unique in frame start that is absent from the full-length sequence (Figures 3 and 4) . We also identified the presence of the full-length sequence in human liver cDNA.
The truncated hrgr transcript is oncogenic
The fact that the truncated transcripts, with the alternative start sites, were only found in the Jurkat tumor cell line and our previous reports indicating that the rabbit rgr oncogene was also truncated led us to hypothesize that the truncation of the hrgr gene might also be oncogenic. The high levels of truncated hrgr observed in the Jurkat cells also hinted to the involvement of the gene in the Jurkat cell phenotype (Figure 2) . To test this hypothesis we compared the biological activity of the Jurkat-derived cDNAs with the full-length normal human transcript. We found that the truncated transcripts were transforming when expressed in 3T3 cells while the full-length transcript was not. These results are consistent with the rabbit rgr results (D'Adamo et al., 1997) in demonstrating that the expression of this truncated transcript, rabbit or human, is in fact oncogenic. The oncogenicity of the truncated hrgr transcript present in Jurkat cells could be due to modified substrate specificity conferred by the truncation. In fact, as we reported previously, a dominant negative ras mutant is able to block the malignant properties induced by a truncated rabbit rgr oncogene while a dominant negative Ral cannot (Hernandez-Mun˜oz et al., 2000) . In addition, it is possible that the truncation has removed translational regulatory controls that facilitate the rgr expression (I Hernandez-Mun˜oz et al., manuscript in preparation).
At the present time only truncated hrgr EST sequences have been entered into the human database. Even more interesting is the fact that in all but one case the truncated hrgr EST sequence was isolated from a tumor source.
Development of an assay to detect the abnormal hrgr transcript
To detect the presence of the abnormal hrgr transcripts we utilized the intronic sequences present in the 5' regions of the truncated transcripts to design primers for RT -PCR. The size of the sequences specific to the abnormal transcript (120 -240 bp) is small, and the 5' sequences alone would be indistinguishable from genomic DNA using PCR amplification. To overcome this difficulty we utilized 3' sequences within a region that is conserved in truncated and normal transcripts but separated from the 5' primer by introns (see Figures 3 and 4) . We initially identified several ALCL lines that were positive for the truncated transcript (Table 1) . Upon analysis of a number of fresh tumors and cell lines we found that B-cell tumors, normal Tcells, tonsil, spleen, or thymus were negative for the abnormal transcript while several T-cell lymphoid malignancies, including mycosis fungoides, ALCL and peripheral T-cell lymphomas (PTCL) were positive. From these results we propose that the expression of the truncated transcript is involved in the malignant phenotype of patients with a subset of T-cell malignancies. It is notable that the very large majority of the PTCL analysed so far carry these abnormal transcripts, suggesting that this tumor may represent a Figure 4 The 3' region of the hrgr transcripts shows alternative splicing and abnormal exons in the truncated transcripts. Several different 3' cDNA sequences have been isolated and sequenced. The presence of additional exons between exons 8 and 9 (we named them exons 8B, 8C and 8D) is restricted to tumor cell lines. Exon map 1 shows all possible exons and it has not been observed yet. The presence of exons 8B, 8C and/or 8D will change the start codon, but it will not change the reading frame for the remainder of the transcript. The addition of the variable exons 12B, 12C or 12CD does change the reading frame for the final exon 13 and in doing so it changes the stop codon. Schemes 2, 3 and 4 were observed and sequenced from a human testis library. Schemes 2 and 4 were observed and sequenced from human liver mRNA. All of the remaining variants were observed in the Jurkat cell line except variant 8 which was only seen in the Karpas cell line. Several of the truncated variations were seen in either the Karpas or the DHL cell lines. The dark and light colored exons are present in all normal transcripts analysed. The striped exons are present only in abnormal transcripts from tumor cells (the arrows indicate the start of translation). The checkered exons are alternative splicing variants. The darkly checkered exons make the transcript use the last stop sign, while the lightly checkered exons make the transcript stop in the middle stop codon. The stars represent the position of the different stop codons used by the different transcripts more homogeneous group of lymphomas than previously thought with possibly specific genetic lesions and/or pathogenesis. Moreover, it would be extremely interesting to determine if the T-cell malignancies, that contain these abnormal hrgr transcripts, might have a more aggressive course.
Genetic events responsible for the expression of the truncated hrgr transcript
In normal human cells the expression level of the rgr gene is low, while we have observed that when transformed cells and tumor samples express the oncogene, the expression is significant. Analysis of the mRNA sequence of the truncated hrgr transcript from the Jurkat cell line revealed the sequence of the normal hrgr cDNA from exon 9 to the 3' end with the additional intronic sequences, now exonic, at the 5' end allowing its translation. The truncated transcript is then initiated at an alternative initiation site that normally falls in an intron. Following identification of other cell lines that expressed the alternative initiation exon using the RT -PCR assay, we were unable to detect by Northern blot a similar transcript as the one observed in Jurkat cells (data not shown). Since they did however exhibit the alternative initiation exon, we hypothesized that these cell lines expressed a rearranged transcript. Analysis of the DHL cell line RNA confirmed this hypothesis since it contained the truncated hrgr sequence preceded by a 140 nucleotide sequence which in the normal genome is found 3' to the hrgr gene ( Figure  6 ). Therefore we hypothesize that there are several mutational mechanisms that are utilized in different malignancies that result in expression of an abnormal hrgr transcript.
The chromosomal localization of the hrgr gene
The chromosomal localization of the hrgr gene is to chromosome 22 at the position 22q11.2. The identification of the location of the hrgr gene together with the knowledge that its activation is associated with gene rearrangement, led us to investigate the frequency of such events in that region of the genome. The translocation present in the Philadelphia chromosome, which is postulated to be the main pathogenic factor in greater than 90% of CML and 30% of ALL (Chissoe et al., 1995) , is localized 100 kb from the hrgr gene. This proximity provides support for the idea that this region of the genome is prone to rearrangements. It is also interesting to note that a BCR like region exists immediately 5' of the hrgr gene. Translocation of the hrgr gene could produce its truncation and/or fusion genes, with the truncated hrgr transcript as a part of the fusion transcript. This could mimic the scenario observed in the rabbit (D'Adamo et al., 1997) . Our analysis also demonstrates the presence of a novel immunoglobulin like gene (Ig Lambda Chain C) within the hrgr gene (data not shown). It is well known that immunoglobulin genes undergo rearrangements particularly in lymphoid cells.
We also found evidence that in the region 5' of the hrgr coding region there are sequences that have a high level of similarity to exons 1 -4 of the hrgr gene (greater than 81%) (data not shown) because this entire genomic region appears to be duplicated. This duplication only encompasses the 5' half of the hrgr gene. This indicates that at some point during evolution a duplication and rearrangement occurred of the hrgr gene or its ancestor. This is a similar type of event to what we postulate to be responsible for the production of the truncated hrgr transcript and activation of its oncogenic potential. The fact that translocation events frequently occur in the same place 'hot spots' (Jiang et al., 1990) is consistent with the hypothesis that chromosomal rearrangements may be responsible for the production of the truncated hrgr transcript in human lymphomas.
In these experiments we have been able to determine that truncation of a Ral exchange factor is able to endow the molecule with transforming capacity, but even more importantly we have been able to uncover several genetic mechanisms which can produce the abnormal transcript in human samples. Finally, oncogenic hrgr transcripts could be detected in a substantial fraction of human peripheral T-cell lymphomas. These results therefore open the way for an additional diagnostic tool for the study of T-cell lymphomas and for a better understanding of their pathogenesis, and eventually to the design of unique and possibly specific therapeutic modalities. Samples used were derived from normal tissue Figure 6 The sequence of the hrgr transcript in DHL cells indicates that the DNA containing the 3' portion of the hrgr gene has undergone a rearrangement. This schematic shows the 3' genomic DNA sequence in black that was found on the 5' end of the truncated hrgr transcript from DHL cells
Materials and methods
Transfection
NIH3T3 cells were transfected with the fusion constructs by the calcium phosphate method (Pellicer et al., 1980) . The cells were then selected for the presence of the plasmid by growth in DMEM media with 10% bovine serum and G418, 200 mg/ ml (Gibco).
Focus formation assay
NIH3T3 cells were seeded at 2610 5 per 10 cm plate. The following day cells were transfected by the calcium phosphate method (Pellicer et al., 1980 ) using 2 ml of precipitate containing 100 ng or 1 mg of plasmid DNA with 10 mg of carrier DNA. After 12 h of incubation at 378C the precipitate was removed and fresh DMEM+10% CS was added. Two days later the cells were trypsinized and split 1 : 3 into 10 cm plates containing DMEM+5% CS. The cells were re-fed every 3 -4 days and foci were scored under the microscope after 3 weeks.
Anchorage independence assay
Growth in soft agar of cell lines derived from NIH3T3 cells was determined as described (Bouck and Di Mayorca, 1979) . Five ml of DMEM+10% CS and 0.63% agarose was poured into each 6 cm plate and allowed to solidify. Cells were trypsinized, counted and drawn through a 20 ga needle to break up clumps. Cells (5610 4 ) in 0.9 ml were combined with 1.1 ml DMEM+10% CS and 0.38% agarose and poured onto the bottom agarose. It was particularly important to keep the agarose at 508C prior to use. The plates were allowed to harden in a sterile hood and then incubated at 378C for 2 -3 weeks re-fed every week. Clusters of cells greater than 30 cells were scored as positives.
Growth in low serum
NIH3T3 (5610 4 ) and the NIH3T3-hrgr transfected cells were plated on 10 cm plates. Cells were grown in DMEM+1% CS. Cells were trypsinized and counted on a hemocytometer at days 1, 4, 8 and 11.
Screening of the human testes cDNA library
The cDNA library purchased from Omnigene had been prescreened with PCR primers specific for the 3' Jurkat fragment of the hrgr cDNA. The method of PCR screening the cDNA library was as described by the manufacturer (Omnigene). Briefly, the cDNA library was subcloned into a PCR 3 eukaryotic expression vector. Bacteria provided by the company were pre-transformed with the cDNA library. An array of pools of bacteria was screened with PCR and the hrgr specific primers. Positive pools very divided into 96 smaller pools. This process was repeated three times and the still remaining positive pools were plated on ampicillin agar plates. Clones from the plates were picked and suspended in LB media. Aliquots of the clones were screened by PCR for the presence of the hrgr cDNA. Positive clones were grown up and maxiprep purified (Quiagen). The purified plasmid cDNA inserts were then sequenced at the Core Sequencing Facility NYU Medical Center.
Northern analysis
RNA was isolated with the Trizol reagent and protocol (Gibco). Northern blotting was performed using agaroseformaldehyde gels (Ausubel et al., 1987) . Probes were labeled with P 32 dCTP using the Redi-Prime random priming kit (Amersham). Transfers were made to nylon membranes (Amersham) and the membranes were exposed to UV radiation in a transiluminator for 10 min for crosslinking. Filters were hybridized overnight at 428C in hybridization solution containing 50% formamide. Final washes were for 15 min at 558C, in 0.l6SSC and 0.1% SDS.
RACE reactions
We utilized several types of RACE reactions. The first was the standard reaction (Clontech). This reaction utilizes a reverse transcription reaction primed with a poly dT primer. The resulting single stranded cDNA is copied with an enzyme cocktail containing DNA Pol I, RNase H and DNA ligase. DNA adaptors are then ligated to the ends of the cDNA. PCR amplification can then be performed using a gene specific primer and an adaptor primer. To amplify full-length 5' ends the GeneRacer technique was used (Invitrogen and Ambion). This technique only utilizes RNA, which is phosphorylated on the 5' end to eliminate all uncapped RNA fragments. Next mRNA caps were removed using tobacco alkaline phosphatase freeing 5' phosphate groups from mRNA that was capped, and therefore full length. The third type of RACE used was the Genewalker (Clontech). This technique was used to walk along genomic DNA, amplifying from a known region to an unknown one. The basis of this technique is to digest the genomic DNA at specific sites using blunt end producing restriction enzymes and then ligating DNA adaptors. The known sequence was then extended with standard PCR. The products of all RACE reactions were subcloned into the PCR2.1 vector (Invitrogen).
PCR assay to detect abnormal transcripts
The forward primer was 5'-ATGACGGTGAGAACAA-CGGCAACAGCTACAGG-3' corresponding to sequences in exon 8B (normally intronic) and therefore not included in the sequence in Figure 1 . The reverse primer sequence was 5'-CGGGTTTTCGGGCTCCAGCTGGCAGG-3' located in exon 13 and its boundaries are 1349 -1419.
